Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nacubactam - Fedora Pharmaceuticals/ Meiji Seika Pharma

Drug Profile

Nacubactam - Fedora Pharmaceuticals/ Meiji Seika Pharma

Alternative Names: FPI-1459; OP-0595; RG 6080; RO 7079901

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fedora Pharmaceuticals
  • Developer Meiji Seika Pharma; Roche
  • Class Antibacterials; Azabicyclo compounds
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Bacterial-infections(Combination therapy) in USA (IV, Infusion)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Bacterial-infections(Monotherapy, In volunteers) in USA (IV, Infusion)
  • 13 Apr 2019 Antimicrobial data from a preclinical studies in Bacterial infections presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top